NDAIntravesical, UreteralSolution
Approved
Apr 1972
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
CYSTO-CONRAY (iothalamate meglumine) by Guerbet is clinical pharmacology the most important characteristic of contrast media is the iodine content. First approved in 1972.
Drug data last refreshed 7h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CYSTO-CONRAY is an iothalamate meglumine contrast medium administered intravesically or ureteral for retrograde urographic visualization of the lower urinary tract. The drug's radiodensity derives from its iodine content, enabling clear visualization during diagnostic imaging procedures. Following instillation via sterile catheter, systemic absorption is typically less than 1% but can reach up to 12% with pyelorenal back flow.
LOE Approaching
Product is in late-stage lifecycle with moderate competitive pressure (30%), suggesting a consolidating team focused on maintaining share rather than expansion.
Mechanism of Action
CLINICAL PHARMACOLOGY The most important characteristic of contrast media is the iodine content. The relatively high atomic weight of iodine contributes sufficient radiodensity for radiographic contrast. Following instillation by sterile catheter, Cysto-Conray II provides for visualization of the…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
CYSTO-CONRAY presents minimal active career opportunities with zero linked jobs currently identified. Working on this product typically involves maintenance-focused roles in brand management, field sales, and medical affairs focused on defending market position and managing cost pressures rather than driving innovation.
Brand Manager
Worked on CYSTO-CONRAY at Guerbet? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.